The company has been selected as 2021 Global TOP 10 Immunotherapy Solution Companies announced by Pharma Tech Outlook. 

Pharma Tech Outlook is an authoritative USA BIO/Healthcare media. Every year, they select global BIO companies with excellent research performance and high business competitiveness. STcube was selected for the first time in Korea and has been recognized worldwide for excellent research achievements on Immunotherapy.

The company plans to initiate global clinical trials upon obtaining IND approval from US food and Drug Administration (FDA) in the second half of this year. Various development options, including co-development with and/or licensing out to multinational pharmaceutical companies, are being explored at the current time.

The STCube interview in the Pharma Tech Outlook can be viewed at the top of the link.